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Neurodegeneration is referred to as the progressive loss of
structure and function of neurons. Neurodegenerative dis-
eases constitute one of the major challenges of modern
medicine, including Alzheimer’s disease, Parkinson’s dis-
ease, Huntington’s disease, Pick’s disease etc.1,2 Alz-
heimer’s disease is characterized by loss of neurons and
synapses in the cerebral cortex region and subcortical re-
gions. This loss results in gross atrophy of the affected re-
gions, including degeneration in the temporal lobe and
parietal lobe, and parts of the frontal cortex and cingulate
gyrus.3e6 Parkinson’s disease is a degenerative disorder of
the central nervous system, the mechanism by which the
brain cells in Parkinson’s are lost may consist of an
abnormal accumulation of the protein alpha-synuclein
bound to ubiquitin in the damaged cells.7e9 The causes of
Huntington’s disease are astrogliosis and loss of medium
spiny neurons. The areas affected are mainly in the stria-
tum, but also the frontal and temporal cortices.10
Many neurodegenerative diseases are caused by genetic
mutations, most of which are completely located in unre-
lated genes. Identification of disease causing genes is one
of the major challenges in the human genome studies. The
use of linkage analysis and cloning techniques has led to the
detection of genes involved in abundant Mendelian genetic
disorders.1,11
Protein kinases are the most common protein domains
implicated in neurodegenerative diseases.12 Kinome is a
division of genome that consists of protein kinase genes.
Protein kinases are major regulatory enzymes that partici-
pate in the process of protein phosphorylation. It is an
essential process in many cellular and signal transduction
processes.13 Protein kinases (PK’s) act as key regulators of
cell functions by catalyzing the addition of a negatively
charged phosphate group to proteins. Because of its role in
every aspect of regulation and signal transduction, they
provide new targets for drug development.14,15
Human (Homo sapiens) share maximum sequence simi-
larity with their closest ancestral species chimpanzee (Pan
troglodytes), gorilla (Gorilla gorilla) and orangutan (Pongo
abelii) genomes.16 Comparing the human genome to the
genomes of other great apes can provide a window into the
molecular changes that causes this difference in disease
susceptibility between human and non-human primates.
The sequence divergence between the human, and chim-
panzee has been a subject of numerous studies.17e19
Human brain aging equally exhibits similarities and differ-
ences with great apes. The amyloid-b protein deposits are
seen in hippocampus and neocortex of aged chimpanzees,gorillas, and orangutans in the form of diffuse plaques and
vascular lesions similar to humans.20,21 But gene expression
changes in the neocortex during aging in human makes
them more susceptible to age related neurodegenerative
diseases.22 Even though it is widely considered that they
are exclusive to the human species, various studies have
shown the existence of some neurodegenerative diseases in
senile non-human primates. They are found to be present
with some features including neuropathological changes
and cognitive-behavioral symptoms, but with lower levels
of incidence.22,23
The discovery of gene mutations dominates our under-
standing of neurodegenerative diseases. However they
have a more complex etiology influenced by lifestyle and
environmental factors in addition to a number of unchar-
acterized variants in a high number of genes. An important
pathological hallmark of ND diseases is usually the accu-
mulation and aggregation of misfolded proteins as with
amyloid-b (Ab) in Alzheimer’s disease (AD),24,25 a-synuclein
in Parkinson’s disease (PD)26 and huntingtin protein in
Huntington’s disease (HD).27 Recently biological pathways
and networks have become focal points to examine the
genetic architecture of neurodegeneration. Vijay K Ram-
anan and Andrew J Saykin28 reviewed the major pathways
implicated in neurodegeneration.
The present study compares the key protein kinase se-
quences of humans, chimpanzee, gorilla and orangutan and
tries to analyze the kinase level evolutionary relationships
among the four lineages. The study of disease susceptibility
genes is an emerging task in the field of genetic research
that could lead to fruitful information.Materials and methods
Hominid protein kinase data sets
In our recent publication,29 we reported in detail about
the collection of hominid protein kinase data sets. The
same is briefly outlined below. Human protein kinases
were directly taken from our in-built database Homo-
Kinase (http://www.biominingbu.org/homokinase).30 For
the other three species e Chimpanzee, Gorilla and
Orangutan, the proteomes were retrieved from Uniprot
data source (http://www.uniprot.org/) and their func-
tional annotation were checked for the presence of the
following three GO terms i) ATP binding, ii) kinase activity,
and iii) protein phosphorylation. Protein with above three
GO annotation terms were classified as true protein ki-
nases and used for further analysis. In total, 499 human,
478 chimpanzee, 468 gorilla and 470 orangutan protein
kinases were used.
Identification and classification of
neurodegenerative disease associated protein
kinases
From the above human protein kinase data set, protein
kinase genes associated with the three target diseases
(Alzheimer’s, Parkinson’s and Huntington’s) were identified
and grouped using OMIM (www.ncbi.nlm.nih.gov/Omim)31
Table 1 Protein kinases associated with Alzheimer’s,
Parkinson’s, and Huntington’s diseases (underlined kinases
have more than one disease association).
Diseases Protein kinases
Alzheimer’s AKT1, CDK1, CDK4, CDK18, CDK5, CDKL1,
CLK2, CSNK2A2, DYRK1A, EEF2K, EIF2AK2,
ERK1, EPHB2, FGFR1, FGFR3, FYN, GSK3A,
GSK3B, JNK1, JNK3, LRRK2, LTK, MAP2K1,
MAP2K4, MAPK14, MARK2, MARK4, P70S6K,
PINK1, PKN1, PRKCA, PRKCG
Parkinson’s CRIK, GPRK5, GSK3B, LRRK1, LRRK2,
MAP3K14, MAPK1, MAPK14, PINK1, PYK2,
R1PK2, ROS, SGK1
Huntington’s DMPK1, EIF2AK1, FGFR3, GPRK6, MAP3K10,
PDK1, PYK2, RIPK2, TRKB
230 S. Jayapalan et al.and Wikigenes (http://www.wikigenes.org/).32 For this, we
used MeSH terms associated with the three diseases (Alz-
heimer’s disease for AD, Parkinson’s disease for PD and
Huntington’s disease for HD) to extract all literature cited
in OMIM. In addition, the set of human neurodegenerative
PKs were also selected from the literature based on
mutational analysis and/or roles in processes such as
chromosomal stability, promoter methylation etc. From the
total of 499 human protein kinases, 47 protein kinases were
found to be associated with neurodegenerative diseases
and subjected to further analysis. Similarly the orthologous
protein kinases present in other three species chimpanzee,
gorilla and orangutan for the above 47 human protein ki-
nases were retrieved from their protein kinase data sets.
Sequence analysis of orthologous protein kinases
Both Multiple sequence alignment (MSA) and pairwise
sequence analysis were performed between all 47 selected
human protein kinases and their orthologous sequence from
other three genomes to find indels and substitutions be-
tween the human PK’s and other orthologs. Multiple
sequence alignment (MSA) for all four genomes was per-
formed using ClustalX 2.133 to find the similarities and
dissimilarities between the orthologous kinases at protein
sequence level. Further, any sequence characteristics
specific to human kinases were also examined for all the
target disease associated protein kinases.
In addition pairwise sequence alignments between
human and other hominid PK’s were performed using
EMBOSS Needle (http://www.sanger.ac.uk/Software/
EMBOSS/)34 program to find the genetic differences be-
tween seven key protein kinases which were associated
with more than one of the target diseases.
Phosphorylation site analysis
The regulation of protein kinase activity is brought about by
various mechanisms in which phosphorylation also plays a
very relevant role. To bring about more insights into this,
the protein phosphorylation sites of a few chosen kinases
with significant results in MSA were predicted using NetPhos
2.0 server35 to identify Ser/Thr and Tyr phosphorylation
sites.
Interaction analysis of selected protein kinases in
humans
In order to identify additional functional relationships be-
tween the AD, PD, and HD associated kinases and to obtain
a deeper understanding of the consequences of the kinases
with phosphorylation sites predicted exclusively in humans,
we analyzed their participation in human signaling path-
ways. Our aim was to examine the participation of the ki-
nases and their targets in neurodegenerative diseases and
important signaling pathways such as EGF/MAPK, neuro-
trophin and Notch signaling pathways. Experimentally
proven targets of these kinases were obtained from STRING
(version 8.3),36 HPRD (version 5)37 and BioGrid (version
3.0.64)38 databases. The gene list of kinases and their tar-
gets were then analyzed for overrepresentation of diseasepathways and important signaling pathways using the on-
line tool WebGeStalt.39 Enrichment analysis was carried out
for KEGG pathways,40 Pathway commons,41 Wikipathways42
and Disease association (from PharmGKB43) in
WebGestalt.39
Results
A set of 499 human, 478 chimpanzee, 468 gorilla and 470
orangutan protein kinases was used for this kinase-disease
association analysis. Then by literature based approaches
and from OMIM31 and Wikigenes32 data bases we retrieved
the human protein kinases associated with neurodegener-
ative diseases (Table 1). These neurodegenerative associ-
ated protein kinases were grouped into three categories:
(1) HPK’s associated with Alzheimer’s disease,
(2) HPK’s associated with Parkinson’s disease and
(3) HPK’s associated with Huntington’s disease.
A total number of 47 protein kinases associated with the
three neurodegenerative diseases were identified and
grouped and given in Table 1. Protein kinases associated
with more than one disease are underlined. The Table 1
results revealed that 32 human protein kinases (HPKs)
were found to be associated with Alzheimer’s diseases, 13
HPKs with Parkinson’s disease and 9 HPKs were associated
with Huntington’s disease. Further seven kinases (LRRK2,
GSK3B, PINK1, MAPK14, FGFR3, PYK2 and R1PK2) of them
being found to be associated with more than one disease.
LRRK2, GSK3B, PINK1 and MAPK14 are commonly associated
with both Alzheimer’s disease and Parkinson’s disease.
FGFR3 is associated with both Alzheimer’s disease and
Huntington’s disease whereas PYK2 and R1PK2 are associ-
ated with both Parkinson’s disease and Huntington’s dis-
ease. The associations have been represented in the form
of a gene-disease network in Fig. 1.
For the above 47 human protein kinases, the orthologous
protein kinases present in chimpanzee, gorilla and orang-
utan were identified and grouped using their respective
protein kinase data sets. Table 2 gives the complete list of
human protein kinases and their corresponding orthologs
from other three species.
Fig. 1 Gene-disease network for Alzheimer’s disease (AD), Parkinson’s disease (PD), and Huntington’s disease (HD).
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Basic sequence analysis was performed to find the
sequence identity similarities and dissimilarities between
the orthologous protein kinases of human and non-human
genomes. The pairwise sequence alignment of seven pro-
tein kinases namely LRRK2, GSK3B, PINK1, MAPK14, FGFR3,
PYK2 and R1PK2 associated with more than one disease
showed that all of them except GSK3B and MAPK14 shared
greater than 95% similarity with each other (Table 3).
Human GSK3B protein sequence was identical to chim-
panzee sequence where as it shared 88.2% and 84.6% sim-
ilarity with the gorilla and orangutan protein sequences,
respectively (Table 3). Significant deviation from human
sequence was observed for FGFR3 sequence of orangutan
genome (70% similarity at protein level with 29.8% gaps)
and MAPK14 sequence of gorilla genome (60.2% similarity at
protein level with 34% gaps). Thus a preliminary analysis of
key protein kinases involved in neurodegenerative diseases
showed high amount of conservation within species.
ClustalX was used to build multiple sequence alignments
of the selected protein kinases. Multiple sequence align-
ments of 47 protein kinases were carried out. For each
human protein kinase under consideration, the protein se-
quences of the corresponding orthologous kinase from the
other three genomes if present were taken for the align-
ment. The results revealed that some of the human kinases
contained many significant indels and substitutions which
are not seen in any of the other sequences. A few signifi-
cant differences observed in three protein kinases DYRK1A,
RPS6KB1, and GRK6 are mentioned below.The protein kinase DYRK1A associated with Alzheimer’s
disease in humans contained a long insertion of 83 amino
acids in human which was not present in any of the corre-
sponding orthologs. DYRK1A sequence contained 763 amino
acids in humans 754 amino acids in chimpanzee 535 amino
acids in gorilla and 683 amino acids in orangutan. The
orangutan DYRK1A sequence was mostly similar to the
human DYRK1A except for this major deletion.
In the case of protein kinase RPS6KB1, also associated
with Alzheimer’s diseases there was a deletion of 22 amino
acid residues in human (Fig. 2a). Terminal amino acid res-
idues were identical in human and orangutan while they
were absent in chimpanzee and gorilla. The sequences
were similar at other positions of the alignment for all the
four genomes.
The protein kinase GRK6 associated with Huntington’s
disease has 560 amino acids in human and 576 in gorilla and
orangutan. The GRK6 sequence in chimpanzee consisted of
600 amino acid residues and was found to vary considerably
from the other three GRK6 sequences. Among the other
three gorilla and orangutan GRK6 contained a sequence
segment of 17 amino acids long which was replaced by a
single ‘R’ residue in human (Fig. 2b).
We also looked for other possible general features and
variations among the protein kinases associated with each
of the three diseases. One important observation was that
in LTK human sequence had a low occurrence of Gly-
repeats compared to the LTK’s of other three organisms.
The Gly repeats were either deleted in between or
substituted with other residues. In addition many other
deletions were also observed in LTK.
Table 2 Human neurodegenerative disease associated protein kinases and their equivalent orthologs in other hominids.
Disease Human protein kinases Chimpanzee Gorilla Orangutan
Alzheimer’s AKT1
CDK1
CDK4
CDK5
CDK18
CDKL1
CLK2
CSNK2A2
DYRK1A
EEF2K
EIF2AK2
EPHB2/ERK
ERK1/MAPK3
FGFR1
FGFR3
FYN
GSK3A
GSK3B
JNK1/MAPK8
JNK3/MAPK10
LRRK2
LTK
MAP2K1
MAP2K4
MAPK14
MARK2
MARK4
P70S6K/RPS6KB1
PINK1
PKN1
PRKCA
PRKCG
AKT1
CDK1
CDK4
CDK5
CDK18
CDKL1
CLK2
CSNK2A2
DYRK1A
EEF2K
EIF2AK2
EPHB2
ERK1
FGFR1
FGFR3
FYN
GSK3A
GSK3B
JNK1
JNK3
LRRK2
LTK
MAP2K1
MAP2K4
MAPK14
e
MARK4
P70S6K
PINK1
PKN1
PRKCA
PRKCG
AKT1
CDK1
CDK4
CDK5
CDK18
CDKL1
CLK2
CSNK2A2
DYRK1A
EEF2K
e
EPHB2
ERK1
FGFR1
FGFR3
FYN
GSK3A
GSK3B
JNK1
JNK3
LRRK2
LTK
MAP2K1
MAP2K4
MAPK14
MARK2
MARK4
P70S6K
PINK1
PKN1
PRKCA
PRKCG
e
CDK1
CDK4
CDK5
CDK18
e
e
CSNK2A2
DYRK1A
EEF2K
EIF2AK2
EPHB2
ERK1
FGFR1
FGFR3
FYN
GSK3A
GSK3B
JNK1
JNK3
LRRK2
LTK
MAP2K1
e
MAPK14
MARK2
MARK4
P70S6K
PINK1
e
e
PRKCG
Parkinson’s CRIK/CIT
GPRK5
GSK3B
LRRK1
LRRK2
MAP3K14
MAPK1
MAPK14
PINK1
PYK2/PTK2B
R1PK2
ROS
SGK1
CRIK
GPRK5
GSK3B
LRRK1
LRRK2
MAP3K14
MAPK1
MAPK14
PINK1
PYK2
R1PK2
ROS
SGK1
CRIK
GPRK5
GSK3B
LRRK1
LRRK2
MAP3K14
e
MAPK14
PINK1
PYK2
R1PK2
ROS
SGK1
CRIK
GPRK5
GSK3B
LRRK1
LRRK2
MAP3K14
MAPK1
MAPK14
PINK1
PYK2
R1PK2
ROS
SGK1
Huntington’s DMPK1
EIF2AK1
FGFR3
GPRK6
MAP3K10
PDK1
PYK2
R1PK2
TRKB
DMPK1
EIF2AK1
FGFR3
GPRK6
MAP3K10
PDK1
PYK2
R1PK2
TRKB
DMPK1
EIF2AK1
FGFR3
GPRK6
MAP3K10
PDK1
PYK2
R1PK2
TRKB
DMPK1
EIF2AK1
FGFR3
GPRK6
MAP3K10
PDK1
PYK2
R1PK2
TRKB
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Table 3 Protein sequence comparison results (in percentage) for the seven protein kinases associated with more than one
disease. It showed high degree of conservation within species.
HumaneChimpanzee HumaneGorilla HumaneOrangutan
Identity Similarity Gaps Identity Similarity Gaps Identity Similarity Gaps
GSK3B 100.0% 100.0% 0.0% 87.5% 88.2% 10.6% 83.6% 84.6% 12.6%
LRRK2 99.2% 99.6% 0.0% 97.3% 97.9% 1.5% 97.6% 98.7% 0.4%
PINK1 99.7% 100.0% 0.0% 99.7% 99.7% 0.0% 98.8% 99.3% 0.0%
MAPK14 100.0% 100.0% 0.0% 57.1% 60.2% 34.0% 99.7% 100.0% 0.0%
FGFR3 95.3% 96.4% 0.5% 96.7% 98.1% 0.1% 69.9% 70.0% 29.8%
PYK2 99.6% 99.8% 0.0% 99.6% 99.9% 0.0% 98.9% 99.5% 0.0%
R1PK2 99.3% 99.4% 0.2% 96.9% 97.8% 0.2% 98.9% 99.3% 0.0%
Fig. 2 a) Deletion of 22 amino acid residues in human RPS6KB1 sequence associated with Alzheimer’s disease. b) Sequence
variation in Huntington’s disease associated GRK6 sequence.
Table 4 Phosphorylation sites present in human protein
kinase sequences.
S.
No
Protein
kinase
NetPhos
score
Position and
sequence segment
containing the site
for phosphorylation
Phosphorylation
site for
01 CDKL1 0.866 273 VPIASRTE *S*
02 DYRK1A 0.576 220 EMKYYIVHL *Y*
03 GSK3A 0.800 458 LTPSSQALT *S*
Computational analysis of hominid PK’s in ND 233Another observation was that 5 out of the 13 kinases
associated with Parkinson’s disease namely LRRK1, LRRK2,
MAP3K14, PYK2 and ROS1 were characterized by the most
number of single amino acid substitutions unlike the genes
associated with other diseases.
In summary, the following 18 kinases were found to
contain significant variations: CDK1, CDKL1, DYRK1A,
EIF2AK2, GSK3A, MAPK8, MAPK10, LTK, MARK2, RPS6KB1,
PRKCG (Alzheimer’s disease associated), LRRK1, MAP3K14,
PYK2, ROS1 (Parkinson’s disease associated), TRKB, GRK6
and EIF2AK1 (Huntington disease associated). However a
substantial proportion of differences may have no func-
tional impact and hence it is important to ascertain the
effect of each of these variations. The details are provided
in Supplementary data SD1.04 JNK3/
MAPK10
0.881 31 QVDVSYIAK *S*
05 LTK 0.995 251 RTQASPEKL *S*
06 MARK2 0.981 648 RRNLSFRFA *S*
07 LRRK1 0.521 37 GAGDTGGKP *T*
08 MAP3K14 0.592 292 ACVDSQKPL *S*Phosphorylation site analysis of selected protein
kinases
The varying regions in the protein kinases identified above
were analyzed in depth for phosphorylations sites specificto humans. 18 kinases found to contain significant indels/
substitutions were further analyzed for phosphorylation
sites in the regions seen only in human kinase sequences.
234 S. Jayapalan et al.CDKL1, DYRK1A, GSK3A, MAPK10, LTK, MARK2, LRRK1 and
MAP3K14 contained specific sites of phosphorylation
exclusive to human genomes only (Table 4).
The phosphorylation sites predicted in these sequences
are of great research interest as they are not present in
the other hominid sequences. These genes could be
important candidates for further research on evolutionary
changes related to neurodegenerative diseases. Phosphor-
ylation scores closer to 1 are deemed reliable. Higher
scoring sites in MARK2 and LTK are deliberated in the dis-
cussion section.
Interaction analysis of the protein kinases with
exclusive phosphorylation sites
The first neighbor interactors of the above eight kinases
which were predicted to contain phosphorylation sites in
humans only were retrieved from various databases and
literature sources such as STRING (version 8.3),33 HPRD
(version 5)34 and BioGrid (version 3.0.64).35 Similarly the
pathways associated with each kinase were retrieved from
KEGG pathway database37 and analyzed using WebGeS-
talt36(Supplementary data SD2).
A network was constructed from the collected data to
visualize the kinaseetarget relationships (Fig. 3). The
MAP3K14 with 40 neighbors, MARK2 with 32 interactors,
GSK3A with 20 interactors, MAPK10 with 19 interactors, and
DYRK1A with 17 interactors were found to be the highly
populated kinases. These kinases were also found to be
connected to each other via a few nodes that interact with
more than one kinase, namely YWHAG, MCL1, MAP2K4,
AKT1, YWHAB and SFN. For the other three kinases e LTK,
LRRK1 and CDKL1 had less than ten interactors and were
disconnected from the other kinases.Fig. 3 The network of selected protein kinases and their targ
interactors; Nodes that interact with more than one protein kina
Interactions.Upon investigating the presence of the eight kinases in
KEGG pathways, we found that only GSK3A, MAPK10 and
MAP3K14 participated in important signaling pathways (see
SD2). However, further scrutiny proved that in spite of this,
six of the highly connected interactors of these nodes were
part of many important signaling pathways in humans. AKT1
participated in 66 pathways, MAP2K4 in 12, YWHAB in 7,
YWHAB in 6, SFN in 4 and MCL1 in 3 KEGG pathways,
including important signaling pathways such as PI3K-Akt,
JAK-STAT, MAPK, TNF signaling pathways etc.
The functional enrichment of all the kinases and their
targets also indicated overrepresentation of many central
signaling pathways of the human body. The KEGG pathways
of Alzheimer’s and Huntington’s from KEGG were clearly
overrepresented in the network with P-values of 0.0003 and
0.0034, respectively (Supplementary data SD3). Disease
association analysis indicated the enrichment of neurode-
generative diseases with a P-value of 8.10e-05, Alzheimer’s
disease with a P-value of 0.0005 and Parkinsons’s disease
with P-value of 0.0343. In addition, all the pathway
enrichment analyses indicate that important signaling
pathways indicated in neurodegenerative pathways are
significantly enriched (see SD3). Thus the insertion of
phosphorylation sites in these human kinases might have
long range consequences.
Discussion
Studies on experimental models are the main sources for
gaining knowledge on the mechanisms of neuro-
degeneration. Non-human primates (NHP) are widely used
as models for studies on neurodegenerative studies as ro-
dent models lack true neurodegeneration. These non-
human primates closely resemble humans in geneticets. Red nodes: Protein kinases. Blue nodes: First neighbor
ses are denoted with a corresponding increase in size. Links:
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istics. Accordingly the development of NHP models for
neurodegenerative diseases holds greater promise for suc-
cess in the discovery of diagnoses treatments and cures
than approaches using other animal species.44,45 The role of
phylogenetically related NHP models in disease research
including Parkinson’s and Alzheimer’s diseases has been
reviewed in detail by Sibal LR and Samson KJ.46 Marvanova
M et al. conducted a microarray analysis and assessed the
changes in global expression profiles for the validation of
non-human primate as experimental models for neurolog-
ical disorders.47
However a few differences have been observed between
the nature of disease in human and non-human primates.
Besides the lower incidence and less intense presentations
of neurodegenerative diseases in primates they are also
found to have the ability to recover spontaneously from a
mild or moderate form of the induced disease.48 We hy-
pothesize that the preliminary differences identified in our
study could be a starting point to detect the cause of higher
rate of neurodegenerative diseases in humans. This pro-
vides a path to detect the possible variations between
human and non-human primates that might serve as major
factors e either primary causes or secondary agents of
disease susceptibility.
The results of the current study on kinases are in
agreement with studies that state high similarity between
hominid genomes. However consequential clues regarding
their variations in disease projection were also obtained.
MARK2 and LTK are found to have high scoring phosphory-
lation sites in humans but which are absent in others.
Phosphorylation plays a very important and established
role in regulating the activity of proteins including kinases.
Specific sequence variations are known to contribute to
their specificities and regulation.49e51 Despite the common
features of protein kinases their interactions with different
substrates are very specific and are known to be regulated
by different methods like secondary messenger bindingFig. 4 a) Phosphorylation site inserted in human MARK2. b) Phos
LTK.phosphorylation at catalytic kinase domain as well as
outside it and by association with adapter and regulatory
subunits.52,53
In the case of MARK2 protein kinase the human sequence
was found to be 90.0%, 94.5% and 89.4% identical to the
sequences in chimpanzee, gorilla and orangutan, respec-
tively. The variations were found to be mainly present to-
wards the beginning and end of the sequences. Around 50
residues of the gorilla and orangutan on the either edges
were characterized by indels and substitutions while the
remaining portions were highly similar to the human
sequence. However a set of 9 residues [NLSFRFARR] was
found to be inserted among the otherwise identical por-
tions (Fig. 4a). To add to this finding, the inserted serine
residue was also a strong site for phosphorylation.
Another important kinase identified to be different in
humans was LTK. Human LTK was found to contain an
exclusive serine phosphorylation site with a high score of
0.995. This site was absent in the non-human primates
and more interestingly the region overlapped with glycine
repeats that are found to be missing in human (Fig. 4b).
An interpro scan of the LTK human sequence further
validated this variation by the absence of ATP binding site
and TM helix domain in humans compared to the LTK
sequence of other hominids. These differences among the
LTK sequences of hominids and the association of LTK
with Alzheimer’s disease in humans could be hence a
possible factor for increased disease susceptibility in
humans.
Then, we carried out exhaustive literature search for
validating the association of these kinases in neurode-
generative diseases, investigated previously. The findings
are briefly summarized below. Microtubule-associated
protein (MAPK)/microtubule affinity-regulating kinases
(MARKs) signaling cascade plays a crucial role in synaptic
plasticity and in neurodegenerative diseases.54 Phosphor-
ylation of human tau protein by MARK2 was demonstrated
to show that MARK2 binds to the N-terminal tail of Tauphorylation site variation and missed glycine repeats in human
236 S. Jayapalan et al.and selectively phosphorylates three major and five minor
serine residues in the repeat domain and C-terminal
tail.55
Similarly, the involvement of protein tyrosine kinases
(PTKs) such as LTK and their phosphorylation in the pa-
thology of Alzheimer’s disease have been investigated
before. Even though, the direct association between LTK
and AD has not been investigated before, we include LTK
(alias PTK1) in our study as data from previous reports
suggest that protein tyrosine kinases are suspected to be
involved in the list of PK’s altered in AD.56 Interestingly, our
studies through sequence and network analysis reinforce
this hypothesis.
JNK3/MAPK10 is a group of serineethreonine protein
kinases known to be involved in neuronal death. MAPK10 in
the brain tissue and cerebrospinal fluids showed a signifi-
cant increase in patients with Alzheimer disease and has
been linked to cognitive decline.57 The involvement of the
kinase in progression of Huntington’s disease has also been
indicated.58
It is proven that impairment in kinases can lead to
aberrated phosphorylation resulting in the pathogenesis of
neurodegenerative diseases.59 The identification of the
presence of specific phosphorylation sites specific to human
kinases thus indicates possible changes in their activity.
Further since kinases catalyze the phosphorylation of a
wide variety of other proteins any change in the activity of
kinase could also result in changes in the activity of other
interacting proteins too.
The pathway enrichment analysis of these kinases and
their targets indicating signaling pathways and neurodegen-
erative disease pathways are a prelude to such effects. Thus
the effect of these kinases might not be immediately evident
but manifested indirectly through the activity of their tar-
gets. It is important to link such genetic differences to their
possible effects in the structure and activity of kinases.Conclusion
A comparison of kinome sequences of four related genomes
has provided new insights into kinship evolutions and vari-
ability. We have compared 47 human protein kinases asso-
ciated with Alzheimer’s disease, Parkinson disease and
Huntington’s diseases with their respective orthologs in
chimpanzee, gorilla and orangutan. The high degree of
conservation of protein kinases associated with neurode-
generative diseases among the hominids impelled us to
analyze the minor changes also in more detail. Some
interesting differences associated with insertion of new
phosphorylation sites in humans whose effects might be
further extended to their targets taking part in important
signaling pathways were revealed. This suggests the
contribution of genetic changes in protein kinases in the
incidence of neurodegenerative diseases. However we
cannot rule out the role of remaining genes other than ki-
nases for the different susceptibility between hominids.
Structural analysis could bring out a significant number of
neurodegenerative disease level mutations that might fall
at structurally equivalent positions within the catalytic
core. Our study provides a pathway to perform experi-
mental analysis of human and other three lineage kinomesin order to enhance our understanding on their specific
biological roles.
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